Company: Tasly Pharmaceutical Group Company Limited
Bloomberg Ticker: 600535 SH
Market capitalization: US $ 3,339 million
Background: Tasly Pharmaceutical Group Company Limited focuses on research, development, production and marketing of modern traditional Chinese medicine (TCM) and chemical medicines. Her flagship product, Dantonic, is mainly in China with a growing international presence, is a cardiovascular TCM medical line.
- The profitable growth rank of 6 had fallen compared to the 5th rank of the previous period
- This is below the average performance compared to 380 large health care companies worldwide
- Profitability rank of 5 was better than the growth rank of 8
- The profitability of 5 had fallen compared to the 4th rank of the previous period
- These are average performance compared to peers
- The growth long of 8 had fallen compared to the 6th rank of the previous period
- This is below the average performance compared to colleagues
Safeguard: This content is only for information purposes. It is not intended as investment advice. Readers are not allowed to regard statements by the author (s) as formal recommendations and must consult their financial adviser before they make investment decisions. Although the information provided is considered accurate, this can include errors or inaccuracies. The author (s) cannot be held liable for all actions taken as a result of reading this article.
#Benchmarking #World #Class #Tasly #Pharmaceutical #Group #Company